Skip to main content

Advertisement

SpringerLink
Log in

Randomised clinical endpoint studies for trastuzumab biosimilars: a systematic review

  • Review
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Purpose

Uptake of biosimilars depends on clinicians and patients having confidence in the evidential basis of marketing approval. The aim of this systematic review was to assess the evidential role of randomised clinical endpoint studies in the marketing approval of trastuzumab biosimilars.

Methods

We searched PubMed for any published reports of randomised studies associated with the five trastuzumab biosimilars approved by the EMA, as on 31 January 2019. We also searched ClinicalTrials.gov for any ongoing studies for other trastuzumab biosimilars.

Results

We identified eight published papers or abstracts for seven randomised clinical endpoint studies for five trastuzumab biosimilars approved by the EMA: four studies in the neoadjuvant setting and three in the first-line metastatic setting. Another six unpublished or ongoing studies for other trastuzumab biosimilars were identified via ClinicalTrials.gov. According to GRADE, and considered in isolation, the randomised studies would be categorised as low-quality evidence because of the use of surrogate endpoints and the small sample size. However, according to GRADE, the totality-of-evidence for each of the five approved trastuzumab biosimilars would be categorised as high quality in that further data would be unlikely to change the conclusion that each biosimilar was not different from Herceptin in any clinically important way.

Conclusion

The pivotal data for each marketing approval was not the randomised clinical endpoint study, but the in vitro analytic characterisation. Regulatory confidence in in vitro analytic characterisation stems from years of experience with manufacturing changes for originator biological medicines. This emphasis on in vitro data, as the most sensitive way to detect clinically important differences, will be a new way of thinking for many oncologists.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. WHO Essential Medicines List 20th Edition. http://www.who.int/medicines/publications/essentialmedicines/en/

  2. Blackwell K, Gligorov J, Jacobs I, Twelves C (2018) The global need for a trastuzumab biosimilar for patients with HER2-positive breast cancer. Clin Breast Cancer 18(2):95–113

    Article  Google Scholar 

  3. Gottlieb S (2018) Capturing the benefits of competition for patients. In: Keynote address by Commissioner Gottlieb to the 2018 FDLI annual conference 2018

  4. Camacho LH (2017) Current status of biosimilars in oncology. Drugs 77(9):985–997

    Article  Google Scholar 

  5. Nelson KM, Gallagher PC (2014) Biosimilars lining up to compete with Herceptin–opportunity knocks. Expert Opin Ther Pat 24(11):1149–1153

    Article  CAS  Google Scholar 

  6. European Medicines Agency (EMA) (2018) European Public Assessment Report. Ontruzant (trastuzumab) Procedure No. EMEA/H/C/004323/0000

  7. European Medicines Agency (EMA) (2018) European Public Assessment Report. Kanjinti (trastuzumab) Procedure No. EMEA/H/C/004361/0000

  8. European Medicines Agency (EMA) (2018) European Public Assessment Report. Herzuma (trastuzumab) Procedure No.EMEA/H/C/002575/0000

  9. European Medicines Agency (EMA) (2018) European Public Assessment Report. Trazimera (trastuzumab) Procedure No.EMEA/H/C/004463/0000

  10. European Medicines Agency (EMA) (2019) European Public Assessment Report. Ogivri (trastuzumab) Procedure No. EMEA/H/C/004916/0000

  11. European Medicines Agency (EMA) (2015) Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues: EMEA/CHMP/BMWP/32775/2005_Rev. 1 Committee for Medicinal products for Human Use (CHMP)

  12. European Medicines Agency (EMA) (2018) Guideline on similar biological medicinal products 4 containing recombinant granulocyte-colony stimulating 5 factor (rG-CSF) DRAFT: EMEA/CHMP/BMWP/31329/2005 Rev 1.2 Committee for Medicinal Product for Human Use (CHMP)

  13. European Medicines Agency (EMA) (2012) Guideline on similar biological medicinal products containing monoclonal antibodies—non-clinical and clinical issues: EMA/CHMP/BMWP/403543/2010 Committee for Medicinal Products for Human Use (CHMP)

  14. Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Giezen TJ, Gravanis I, Heim HK, Heinonen E, Ho K et al (2012) Biosimilars: what clinicians should know. Blood 120(26):5111–5117

    Article  CAS  Google Scholar 

  15. Lemery SJ, Ricci MS, Keegan P, McKee AE, Pazdur R (2017) FDA’s approach to regulating biosimilars. Clin Cancer Res 23(8):1882–1885

    Article  Google Scholar 

  16. Food and Drug Administration (FDA) (2017) Considerations in demonstrating interchangeability with a reference product, Guidance for Industry, Draft. In: U.S. Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER)

  17. Im Y-H, Odarchenko P, Grecea D, Komov D, Anatoliy CV, Gupta S (2013) Double-blind, randomized, parallel group, phase III study to demonstrate equivalent efficacy and comparable safety of CT-P6 and trastuzumab, both in combination with paclitaxel, in patients with metastatic breast cancer (MBC) as first-line treatment. J Clin Oncol 31(5):629

    Google Scholar 

  18. Lammers PE, Dank M, Masetti R, Abbas R, Hilton F, Coppola J, Jacobs I (2018) Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer. Br J Cancer 119(3):266–273

    Article  CAS  Google Scholar 

  19. Pegram M, Tan-Chiu E, Freyman A, Vana A, Hilton F, Zacharchuk C, Ewesuedo R (2017) A randomized, double-blind study of PF-05280014 (a potential trastuzumab biosimilar) vs trastuzumab, both in combination with paclitaxel, as first-line treatment for HER2-positive metastatic breast cancer (Abstract 238PD). Ann Oncol 28:v74. https://doi.org/10.1093/annonc/mdx1365

    Article  Google Scholar 

  20. Pivot X, Bondarenko I, Nowecki Z, Dvorkin M, Trishkina E, Ahn JH, Im SA, Sarosiek T, Chatterjee S, Wojtukiewicz MZ et al (2018) A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: final safety, immunogenicity and survival results. Eur J Cancer 93:19–27

    Article  CAS  Google Scholar 

  21. Pivot X, Bondarenko I, Nowecki Z, Dvorkin M, Trishkina E, Ahn JH, Vinnyk Y, Im SA, Sarosiek T, Chatterjee S et al (2018) Phase III, randomized, double-blind study comparing the efficacy, safety, and immunogenicity of SB3 (trastuzumab biosimilar) and reference trastuzumab in patients treated with neoadjuvant therapy for human epidermal growth factor receptor 2-positive early breast cancer. J Clin Oncol 36(10):968–974

    Article  CAS  Google Scholar 

  22. Rugo HS, Barve A, Waller CF, Hernandez-Bronchud M, Herson J, Yuan J, Sharma R, Baczkowski M, Kothekar M, Loganathan S et al (2017) Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: a randomized clinical trial. JAMA 317(1):37–47

    Article  CAS  Google Scholar 

  23. Stebbing J, Baranau Y, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, Zhavrid E, Boliukh D, Stroyakovskii D, Pikiel J et al (2017) CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. Lancet Oncol 18(7):917–928

    Article  CAS  Google Scholar 

  24. von Minckwitz G, Colleoni M, Kolberg HC, Morales S, Santi P, Tomasevic Z, Zhang N, Hanes V (2018) Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial. Lancet Oncol 19(7):987–998

    Article  Google Scholar 

  25. Rugo HS, Curigliano G, Cardoso F, Gradishar WJ, Pegram M, Barrios CHH, CortesCastan J, Pennella E, Muniz R (2018) 324P settings-based efficacy comparison of trastuzumab biosimilars in breast cancer: a systematic literature review. Ann Oncol 29(suppl_8):mdy272.314–mdy272.314

    Google Scholar 

  26. Pivot X, Petit T (2018) Can we establish a hierarchy among trastuzumab biosimilar candidates? Br J Cancer 119(3):263–265

    Article  CAS  Google Scholar 

  27. Biosimilars of trastuzumab. http://www.gabionline.net/Biosimilars/General/Biosimilars-of-trastuzumab

  28. European Medicines Agency (EMA) (2006) Refusal Assessment Report Alpheon (recombinant human interferon-alfa-2a) Procedure No. EMEA/H/C/000585

  29. European Medicines Agency (EMA) (2015) Refusal Assessment Report. Solumarv (human insulin). Procedure No. EMEA/H/C/003858/0000

  30. Jackisch C, Scappaticci FA, Heinzmann D, Bisordi F, Schreitmuller T, Minckwitz G, Cortes J (2015) Neoadjuvant breast cancer treatment as a sensitive setting for trastuzumab biosimilar development and extrapolation. Fut Oncol 11(1):61–71

    Article  CAS  Google Scholar 

  31. Cortes J, Curigliano G, Dieras V (2014) Expert perspectives on biosimilar monoclonal antibodies in breast cancer. Breast Cancer Res Treat 144(2):233–239

    Article  CAS  Google Scholar 

  32. Stebbing J, Baranau Y, Manikhas A, Lee SJ, Thiruchelvam P, Leff D, Esteva FJ (2018) Total pathological complete response versus breast pathological complete response in clinical trials of reference and biosimilar trastuzumab in the neoadjuvant treatment of breast cancer. Expert Rev Anticancer Ther 18(6):531–541

    Article  CAS  Google Scholar 

  33. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30(15):1796–1804

    Article  Google Scholar 

  34. DeMets DL, Cook T (2018) Challenges of non-intention-to-treat analyses. JAMA 321:145

    Article  Google Scholar 

  35. Wangge G, Klungel OH, Roes KC, de Boer A, Hoes AW, Knol MJ (2010) Room for improvement in conducting and reporting non-inferiority randomized controlled trials on drugs: a systematic review. PLoS ONE 5(10):e13550

    Article  Google Scholar 

  36. Rehal S, Morris TP, Fielding K, Carpenter JR, Phillips PP (2016) Non-inferiority trials: are they inferior? A systematic review of reporting in major medical journals. BMJ Open 6(10):e012594

    Article  Google Scholar 

  37. Mauri L, D’Agostino RB Sr (2017) Challenges in the design and interpretation of noninferiority trials. N Engl J Med 377(14):1357–1367

    Article  Google Scholar 

  38. Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim SB, Pienkowski T, Lichinitser M, Semiglazov V, Melichar B et al (2012) Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol 13(9):869–878

    Article  CAS  Google Scholar 

  39. Kim S, Song J, Park S, Ham S, Paek K, Kang M, Chae Y, Seo H, Kim HC, Flores M (2017) Drifts in ADCC-related quality attributes of Herceptin(R): impact on development of a trastuzumab biosimilar. MAbs 9(4):704–714

    Article  CAS  Google Scholar 

  40. Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK (2014) Biosimilars: the science of extrapolation. Blood 124(22):3191–3196

    Article  CAS  Google Scholar 

  41. Guyatt G, Vist G, Falck-Ytter Y, Kunz R, Magrini N, Schunemann H (2006) An emerging consensus on grading recommendations? ACP J Club 144(1):A8–9

    PubMed  Google Scholar 

  42. Vezer B, Buzas Z, Sebeszta M, Zrubka Z (2016) Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents. Curr Med Res Opin 32(5):829–834

    Article  CAS  Google Scholar 

  43. Hiller L, Dunn JA, Loi S, Vallier AL, Howe DL, Cameron DA, Miles D, Wardley AM, Earl HM (2018) Adjuvant trastuzumab duration trials in HER2 positive breast cancer—what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results. BMC Cancer 18(1):391

    Article  Google Scholar 

  44. Lemery SJ (2017) When one is a hammer, everything looks like a nail. J Oncol Pract 13:10s–11s

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia

    Michael Coory & Kate Thornton

Authors
  1. Michael Coory
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kate Thornton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Coory.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

Informed consent

All the studies included in this systematic review were listed in ClinicalTrials.gov, which confirmed that written informed consent was obtained from all individual participants included in the studies.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Coory, M., Thornton, K. Randomised clinical endpoint studies for trastuzumab biosimilars: a systematic review. Breast Cancer Res Treat 176, 17–25 (2019). https://doi.org/10.1007/s10549-019-05227-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-019-05227-7

Keywords

Search

Navigation